LFCRNasdaqPharmaceutical PreparationsFiscal year ends May 25
LIFECORE BIOMEDICAL, INC. DE
Financials through Q4 FY2025, quarter ended May 25, 2025Last filing: 10-Q on Aug 5, 2026
$6.39+0.01 (+0.16%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
31.3%+6.7 pts over 5 years
Operating margin
-13.4%+2.8 pts over 5 years
Net margin
-30.0%−6.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +0.5% | +5.0% | -4.2% | -13.3% | |
| Gross profit | -3.7% | +1.0% | +0.5% | -4.7% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -5.4% | -15.3% | -612.1% | |
| Return on assets | -3.4% | -9.4% | -15.7% | |
| Current ratio | 1.53 | 0.96 | 2.84 | |
| Debt to equity | 0.26 | 0.49 | – | |
| Net debt to EBITDA | -3.91× | -15.97× | – | |
| Interest coverage | -10.4× | -5.6× | -0.8× | |
| Inventory turnover | 16.2× | 2.0× | 2.5× | |
| Capex to revenue | 8.3% | 7.6% | 10.4% | |
| Diluted shares | 27M | 29M | 35M |
Cash use needs five years of cash flow figures
Lifecore Biomedical, Inc. De does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-30.0%
×Asset turnover0.52×
×Equity multiplier38.99×
=Return on equity, FY2025-612.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -30.0% | 0.52× | 38.99× | -612.1% |
| FY2024 | 9.4% | 0.51× | 71.63× | 339.1% |
| FY2023 | -96.4% | 0.39× | 6.32× | -238.2% |
| FY2022 | -104.9% | 0.29× | 2.68× | -80.6% |
| FY2021 | -32.0% | 0.25× | 1.84× | -15.0% |
| FY2020 | -23.9% | 0.39× | 1.63× | -15.3% |
| FY2019 | 0.1% | 1.21× | 1.77× | 0.2% |
| FY2018 | 4.7% | 1.37× | 1.59× | 10.4% |
| FY2017 | 2.3% | 1.34× | 1.60× | 4.8% |
| FY2016 | -2.4% | 1.38× | 1.61× | -5.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$38.72M
- Cash generatingOperating cash flow above zero-$206.00K
- Return on assets improvedROA up on the prior year4.7% → -15.2%
- Earnings backed by cashOperating cash flow above net income-$206.00K vs -$38.72M
- Less leverageLong-term debt to assets fell39.7% → –
- Better liquidityCurrent ratio rose2.08 → 2.84
- No dilutionShare count did not rise37M → 35M
- Gross margin improvedGross margin up on the prior year32.63% → 31.27%
- More efficientAsset turnover rose0.51 → 0.51